Novel lipid-lowering therapies targeting ANGPTL3 and Lp(a)
- PMID: 35449408
- DOI: 10.1038/s41569-022-00715-8
Novel lipid-lowering therapies targeting ANGPTL3 and Lp(a)
Comment on
-
Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals With Elevated Plasma Lipoprotein(a) Levels.JAMA. 2022 May 3;327(17):1679-1687. doi: 10.1001/jama.2022.5050. JAMA. 2022. PMID: 35368052 Free PMC article. Clinical Trial.
-
Effect of Vupanorsen on Non-High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70.Circulation. 2022 May 3;145(18):1377-1386. doi: 10.1161/CIRCULATIONAHA.122.059266. Epub 2022 Apr 3. Circulation. 2022. PMID: 35369705 Free PMC article. Clinical Trial.
References
Original article
-
- Bergmark, B. A. et al. Effect of vupanorsen on non-high-density lipoprotein cholesterol levels in statin-treated patients with elevated cholesterol: TRANSLATE-TIMI 70. Circulation https://doi.org/10.1161/CIRCULATIONAHA.122.059266 (2022) - DOI - PubMed - PMC
-
- Nissen, S. E. et al. Single ascending dose study of a short interfering RNA targeting lipoprotein(a) production in individuals with elevated plasma lipoprotein(a) levels. JAMA https://doi.org/10.1001/jama.2022.5050 (2022) - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
